Literature DB >> 32430649

Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery.

Carmine Antonio Donofrio1, Andrea Cavalli2, Marco Gemma3, Lucia Riccio2, Alessandra Donofrio4, Pietro Panni2, Camillo Ferrari da Passano2, Antonella Del Vecchio5, Angelo Bolognesi6, Riccardo Soffietti7, Pietro Mortini2.   

Abstract

Brain metastases (BM) represent the most common intracranial malignancy in adults. Limitations of existing prognostic models reduce their predictivity and clinical applicability. The aim of this study is to validate the cumulative intracranial tumour volume prognostic assessment (CITVPA) as a new prognostic score system for patients with BM treated by Stereotactic Radiosurgery (SRS). Between January 2001 and December 2015, 1894 patients underwent Gamma Knife SRS treatment. The CITVPA model was implemented and validated as follows: the CITV cut-offs were identified thanks to a receiver-operating characteristic (ROC) curve analysis; the survival predictive factors were selected through a Cox proportional hazard model; its prognostic power was compared to RPA, SIR and GPA through the Harrel concordance index (HCI). According to the ROC curve analysis, the CITV cut-off values were set at 1.5 and 4.0 cc. Based on the multivariate analysis, the CITVPA model included: age (OR 1.010, 95% CI 1.005-1.015, p < 0.001), KPS (OR 0.960, 95% CI 0.956-0.965, p < 0.001), extracranial metastases (OR 1.287, 95% CI 1.154-1.437, p < 0.001), BM number (OR 1.193, 95% CI 1.047-1.360, p = 0.008), and CITV (OR 1.028, 95% CI 1.020-1.036, p < 0.001). A score between 0 and 1 was attributed to each prognosticator; a global CITVPA score ranging from 0 to 5 was assigned with higher results corresponding to worse outcomes. The CITVPA (HCI = 0.64) exhibited a significantly (p < 0.001) higher prognostic power compared to RPA (HCI = 0.55), SIR (HCI = 0.55) and GPA (HCI = 0.61). The CITVPA represents a reliable prognostic system for patients with BM treated by SRS. However, further prospective and multicentric studies are necessary before its applicability in clinical practice.

Entities:  

Keywords:  Brain metastases; Cumulative intracranial tumour volume; Prognostic score system; Stereotactic radiosurgery

Mesh:

Year:  2020        PMID: 32430649     DOI: 10.1007/s10585-020-10037-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

Review 1.  The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.

Authors:  Minesh P Mehta; May N Tsao; Timothy J Whelan; David E Morris; James A Hayman; John C Flickinger; Michael Mills; C Leland Rogers; Luis Souhami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults With Metastatic Brain Tumors.

Authors:  Jerome J Graber; Charles S Cobbs; Jeffrey J Olson
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

4.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Whole Brain Radiation Therapy in Adults With Newly Diagnosed Metastatic Brain Tumors.

Authors:  Laurie E Gaspar; Roshan S Prabhu; Alia Hdeib; D Jay McCracken; George F Lasker; Michael W McDermott; Steven N Kalkanis; Jeffrey J Olson
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

5.  Radiosurgery alone for 5 or more brain metastases: expert opinion survey.

Authors:  Jonathan P S Knisely; Masaaki Yamamoto; Cary P Gross; William A Castrucci; Hidefumi Jokura; Veronica L S Chiang
Journal:  J Neurosurg       Date:  2010-12       Impact factor: 5.115

6.  Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data.

Authors:  Faith G Davis; Therese A Dolecek; Bridget J McCarthy; John L Villano
Journal:  Neuro Oncol       Date:  2012-08-16       Impact factor: 12.300

7.  Treatment trends for patients with brain metastases: Does practice reflect the data?

Authors:  Kiri A Sandler; Narek Shaverdian; Ryan R Cook; Amar U Kishan; Christopher R King; Isaac Yang; Michael L Steinberg; Percy Lee
Journal:  Cancer       Date:  2017-02-08       Impact factor: 6.860

Review 8.  Stereotactic Radiosurgery for Treatment of Brain Metastases.

Authors:  Shahed N Badiyan; William F Regine; Minesh Mehta
Journal:  J Oncol Pract       Date:  2016-08       Impact factor: 3.840

9.  Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.

Authors:  Haley R Gittleman; Quinn T Ostrom; Chaturia D Rouse; Jacqueline A Dowling; Peter M de Blank; Carol A Kruchko; J Bradley Elder; Steven S Rosenfeld; Warren R Selman; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

10.  Epidemiology and prognosis of brain metastases.

Authors:  Keith J Stelzer
Journal:  Surg Neurol Int       Date:  2013-05-02
View more
  1 in total

1.  Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates.

Authors:  Cheng Zhou; Changguo Shan; Mingyao Lai; Zhaoming Zhou; Junjie Zhen; Guanhua Deng; Hainan Li; Juan Li; Chen Ren; Jian Wang; Ming Lu; Liang Zhang; Taihua Wu; Dan Zhu; Feng-Ming Spring Kong; Longhua Chen; Linbo Cai; Lei Wen
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.